Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer by Ledermann, Jonathan A et al.
Quality of life during olaparib maintenance
therapy in platinum-sensitive relapsed serous
ovarian cancer
Jonathan A Ledermann*,1, Philipp Harter2, Charlie Gourley3, Michael Friedlander4, Ignace Vergote5,
Gordon Rustin6, Clare Scott7, Werner Meier8, Ronnie Shapira-Frommer9, Tamar Safra10, Daniela Matei11,
Anitra Fielding12, Bryan Bennett12,14, David Parry12, Stuart Spencer12, Helen Mann12 and Ursula Matulonis13
1University College London, Cancer Research UK and UCL Cancer Trials Centre, 90 Tottenham Court Road, London W1T 4TJ,
UK; 2Kliniken Essen Mitte, Henricistrae 95, D-45136 Essen, Germany; 3University of Edinburgh Cancer Research UK Centre,
MRC IGMM, Western General Hospital, Crewe Road South, Edinburgh EH4 2XR, UK; 4UNSW Clinical School, Prince of Wales
Hospital, High Street, Randwick, NSW 2031, Australia; 5University of Leuven, Herestraat 49, 3000 Leuven, Belgium; 6Mount
Vernon Hospital, Rickmansworth Road, Northwood HA6 2RN, UK; 7Royal Melbourne Hospital, 300 Grattan Street, Parkville,
Victoria 3050, Australia; 8Evangelisches Krankenhaus, Kirchfeldstrae 40, 40217 Du¨sseldorf, Germany; 9Chaim Sheba Medical
Center, Derech Sheba 2, Tel Hashomer 52621, Israel; 10Tel Aviv Sourasky Medical Center, 6 Weizmann Street, Tel Aviv 64239,
Israel; 11Indiana University School of Medicine, 980 West Walnut Street, Indianapolis, IN 46202, USA; 12AstraZeneca,
Mereside, Alderley Park, Macclesfield SK10 4TG, UK and 13Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA
02215, USA
Background: Maintenance monotherapy with the poly(ADP-ribose) polymerase inhibitor olaparib significantly
prolongs progression-free survival over placebo in patients with platinum-sensitive relapsed serous ovarian cancer, with
greatest benefit seen in patients with a BRCA1/2 mutation (BRCAm). Preservation of health-related quality of life (HRQoL)
is important during maintenance therapy; we evaluated the effect of olaparib on HRQoL in this Phase II trial (NCT00753545,
Study 19).
Methods: Patients received olaparib 400mg b.i.d. (capsules) or placebo until progression. Patient-reported HRQoL and disease-
related symptoms were evaluated using the FACT-Ovarian (FACT-O) questionnaire (completed at baseline and every 28 days until
progression), the FACT/NCCN Ovarian Symptom Index (FOSI) and the Trial Outcome Index (TOI). TOI of the FACT-O was the
primary measure.
Results: Overall, 265 women were randomised to maintenance olaparib (n¼ 136) or placebo (n¼ 129). Compliance for HRQoL
assessment was high (B80% over time). Most patients in both arms reported a best response of ‘no change’ on TOI (81%) and
other HRQoL measures. There were no statistically significant differences in time to worsening or improvement rates of TOI, FOSI
and FACT-O scores in the overall, BRCAm and germline BRCAm populations.
Conclusions: Maintenance treatment with olaparib was well tolerated and had no adverse impact on HRQoL in this study of
patients with platinum-sensitive relapsed serous ovarian cancer who had responded to their most recent platinum-based therapy
(partial or complete response). Interpretation of the HRQoL results in this population may differ from patients who have not
responded to their most recent platinum-based therapy.
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Health-related quality of life (HRQoL) is a multidimensional
concept encompassing: physical, cognitive and emotional well-
being; social functioning domains; disease-related symptoms;
therapy-induced side effects; and potential financial and family
burden. These HRQoL measures are a particularly important
consideration in the maintenance setting after response to
chemotherapy, when the majority of patients do not have any
symptoms related to recurrent cancer, as the aim of maintenance
treatment is to prolong the time to progression and to delay the
need for further chemotherapy without compromising the quality
of life of the patients on treatment (Friedlander and King, 2013).
Olaparib (Lynparza) is an oral poly(ADP-ribose) polymerase
(PARP) inhibitor that blocks base-excision repair by trapping
PARP at sites of DNA damage, leading to synthetic lethality in
tumour cells with deficiencies in homologous recombination
repair, such as those with BRCA1/2 mutations (BRCAm) (Evers
et al, 2008; Rottenberg et al, 2008). Olaparib has been extensively
studied and in several Phase II trials, olaparib monotherapy
exhibited antitumour activity in patients with breast and ovarian
cancer, particularly in those with BRCAm (Audeh et al, 2010; Tutt
et al, 2010; Gelmon et al, 2011). In December 2014, olaparib
obtained regulatory approval in the EU as maintenance mono-
therapy for adult patients with platinum-sensitive recurrent (PSR)
BRCAm (germline and/or somatic) high-grade serous ovarian
cancer (SOC), fallopian tube or primary peritoneal cancer, who are
in complete or partial response to platinum-based chemotherapy.
This EU approval was based on the results of a randomised,
double-blind, placebo-controlled, Phase II study (NCT00753545,
D0810C00019, Study 19), in which maintenance monotherapy
with olaparib (capsules) significantly prolonged progression-free
survival (PFS) vs placebo in patients with PSR SOC and patients
with a BRCAm were most likely to benefit from treatment
(Ledermann et al, 2012, 2014). The toxicity profile from this study
demonstrated that adverse events (AEs) were manageable in most
patients (Ledermann et al, 2012, 2014). Dose reductions were
performed as a result of AEs in 24% and 4% of patients in the
olaparib and placebo arms, respectively. The common AEs of
nausea, vomiting, fatigue and anaemia led to dose reduction in 4%,
3%, 4% and 4% of olaparib patients (0%, 1%, 1% and 1% of placebo
patients), respectively. The discontinuation rate as a result of AEs
was 4.4% for olaparib patients and 1.6% for placebo patients.
HRQoL was assessed as a secondary objective in this study and we
report the impact of olaparib on HRQoL and disease-related
symptoms.
MATERIALS AND METHODS
Study design and patients. In this Phase II trial (NCT00753545),
adult patients with platinum-sensitive, relapsed, high-grade SOC
who had received at least two platinum-based regimens and had a
partial or complete response to their most recent platinum-based
regimen were enrolled (Ledermann et al, 2012). Patients were
randomised to receive olaparib 400mg capsules or placebo twice
daily within 8 weeks of completing platinum-based chemotherapy.
Assessment of BRCAm status was not required at enrolment and
was either reported on case report forms after local testing or
established retrospectively using blood samples (germline BRCAm
(gBRCAm)) and/or archival tumour samples (tumour BRCAm)
(Ledermann et al, 2014). The trial design, including inclusion/
exclusion criteria, and a planned retrospective analysis of outcomes
by BRCA status have been published previously (Ledermann et al,
2012, 2014). The secondary endpoints reported here had the same
data cut-off as the primary analysis (30 June 2010). All patients
provided written informed consent. The institutional review boards or
independent ethics committees of all investigational sites approved the
protocol. The study was performed in accordance with the
Declaration of Helsinki, Good Clinical Practice and the AstraZeneca
Policy on Bioethics (AstraZeneca, 2015).
HRQoL tool selection. HRQoL analysis assessed the impact of
maintenance therapy with olaparib, relative to placebo, on HRQoL
and disease-related symptoms in patients with PSR SOC. HRQoL
was assessed using the Functional Assessment of Cancer Therapy
Ovarian (FACT-O) questionnaire, which is a multidimensional
questionnaire developed and validated for ovarian cancer patients.
The FACT-O questionnaire was linguistically validated in multiple
languages; however, no Ukrainian translation was available.
Assessments. The FACT-O questionnaire comprises questions
regarding physical, social, emotional and functional wellbeing and
additional concerns (n¼ 7, 7, 6, 7 and 12 items, respectively;
Supplementary Material and Supplementary Figure S1).
The Trial Outcome Index (TOI), a subset analysis of the
FACT-O, was the primary HRQoL measure. Whereas the FACT-O
score derives from 39 items (score range: 0 152; higher score
indicates better health state), the TOI score derives from 26
physical and functional wellbeing items and ovarian cancer
concerns subscales (score range: 0 104).
The Functional Assessment of Cancer Therapy/National
Comprehensive Cancer Network Ovarian Symptom Index (FOSI)
assessment derives from eight symptom-related FACT-O items
(score range 0 32). Individual concepts of nausea, vomiting and
fatigue were assessed from specific FACT-O questions (‘I have
nausea’, ‘I have been vomiting’, ‘I have a lack of energy’) that were
also captured in FOSI scores (Supplementary Material).
There is currently no standard HRQoL assessment for use in
oncology maintenance clinical trials; the TOI of the FACT-O was
chosen as the primary HRQoL assessment in this study because it
is a validated tool and contained the most concepts of importance
to ovarian cancer patients and those that a pharmacological
product would be expected to impact (physical well-being,
functional well-being and specific concerns for ovarian cancer
patients). The FACT-O is a multidimensional questionnaire
developed and validated for use by ovarian cancer patients; it
includes the 27-item FACT-General (FACT-G) targeted to general
cancer patients and 12 questions specific to issues faced by ovarian
cancer patients (FACT-O subscale). The FACT-G questionnaire
includes the following four subscales: physical well-being (PWB;
seven items), social well-being (seven items), emotional well-being
(six items) and functional well-being (FWB; seven items). These
subscales can be analyzed separately or aggregated to produce a
total HRQoL score. The FACT-G has demonstrated reliability,
validity and responsiveness to change over time (Cella et al, 1993).
Two of the FACT-G subscales (PWB and FWB) plus the FACT-O
subscale are summed to represent the TOI.
Analyses. Patients completed the FACT-O questionnaire at base-
line and monthly until progression. If patients discontinued for
reasons other than progression (assessed by Response Evaluation
Criteria in Solid Tumours (RECIST)), HRQoL assessments
continued until progression was confirmed. Individual symptom
severity over the previous 7 days was measured using the five-item
Likert scale (not at all (0), a little bit (1), somewhat (2), quite a bit
(3) and very much (4)). Better wellbeing was generally indicated by
higher scores; where appropriate, raw scores were reversed
(Supplementary Material).
Improvement and worsening rates in HRQoL values were
evaluated against prospectively determined minimally important
differences relevant to each endpoint (Supplementary Material)
(Osoba et al, 2005).
A retrospective exploratory analysis using linear mixed-model
repeated-measures (MMRM) modelling, adjusting for score at
baseline, time and treatment-by-time interaction, estimated the
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mean effect over time for HRQoL (Stockler et al, 2014). Estimates
of the least-squares means for treatment effects within and between
treatment groups were reported with corresponding 95% con-
fidence intervals (CIs). Mixed-model repeated-measures analyses
were performed on the overall population, as well as the BRCAm
and gBRCAm subgroups.
RESULTS
Patients. Baseline demographics have been reported for the
overall population and BRCAm subgroups (Ledermann et al,
2012, 2014) and are summarised, alongside data for gBRCAm
patients, in Table 1. No significant differences in patient
demographics were observed between treatment groups. Following
retrospective gBRCAm and somatic BRCAm testing, BRCAm status
data were available for 254 of 265 patients (96%), of whom 136 of
254 (54%) had a known/suspected deleterious gBRCAm and/or
somatic BRCAm (Ledermann et al, 2014). Ninety-six patients
(36%) had a gBRCAm (Ledermann et al, 2014).
For the 265 randomised patients (n¼ 136 olaparib, n¼ 129
placebo), compliance with study treatment was good (mean 97%
(standard deviation (s.d.) 9%) olaparib, mean 99% (s.d. 3%)
placebo). Compliance rates for TOI, FOSI and FACT-O assessment
were high at baseline and similar in each arm (85%, 86% and 84%
for olaparib-treated patients vs 86%, 89% and 86% for placebo-
treated patients, respectively). Overall compliance rates over 16
months were also high (69%, 70% and 69% for olaparib-treated
patients and 69%, 70% and 69% for placebo-treated patients,
respectively). Compliance rates over time for the first 6 months of
treatment for TOI, FACT-O and FOSI are detailed in
Supplementary Table S1. A total of 41 patients were excluded
from HRQoL analyses (15%; n¼ 23 olaparib, n¼ 18 placebo); 33
(12%; n¼ 19 olaparib, n¼ 14 placebo) did not complete the
FACT-O questionnaire at baseline or were not evaluable for
FACT-O/TOI and were excluded from HRQoL analyses. Of these
patients, 14 required a Ukrainian translation (n¼ 9 olaparib, n¼ 5
placebo), which was unavailable, 20 did not receive the
questionnaire because of administrative failure (n¼ 11 olaparib,
n¼ 9 placebo), two patients (olaparib) were not evaluable for
FACT-O and five patients were not evaluable for FACT-O and
TOI (n¼ 1 olaparib, n¼ 4 placebo). Patient-level HRQoL data
were collected until either progression or the primary analysis. As
the median PFS from randomisation after the end of chemotherapy
was 4.8 months in the placebo arm, the majority of placebo
patients (68%) did not contribute HRQoL data beyond 6 months.
Therefore, no data are presented beyond 6 months.
HRQoL. At baseline mean (standard deviation) scores were
balanced between olaparib- and placebo-treated patients for all
assessments (TOI, FOSI and FACT-O; Table 2). Across the overall,
BRCAm and gBRCAm groups, most patients achieved best HRQoL
responses of ‘no change’ (Table 2). Results from MMRM analyses
involving BRCAm or gBRCAm patients were consistent with
results from patients irrespective of BRCAm status.
TOI. Most patients reported a best response of ‘no change’
(Table 2); statistical analysis of improvement rates showed no
statistically significant difference between treatment groups in the
overall population (odds ratio (OR) 1.14; 95% CI 0.58, 2.24;
P¼ 0.7). For BRCAm and gBRCAm patients, there was no
statistically significant difference in improvement rates, although
numerically more patients receiving olaparib had a best response of
‘improved’ vs placebo (BRCAm: 25% vs 19%, respectively; OR 1.37;
95% CI 0.56, 3.46; P¼ 0.5; gBRCAm: 27% vs 8%, respectively;
OR 4.08; 95% CI 1.11, 19.9; P¼ 0.03), indicating no detriment to
HRQoL. Supplementary Table S2 provides further details for the
time-to-worsening analysis using Cox’s proportional hazards
model for TOI.
Patients had high baseline TOI scores (mean±s.d., 81.7±11.8
with olaparib and 81.5±11.6 with placebo in the overall
population; 79.9±12.1 and 79.5±12.1, respectively, for BRCAm
patients; 79.5±12.3 and 81.0±11.0, respectively, for gBRCAm
patients), with TOI scores remaining consistent over time and
similar between groups (Figure 1a–c and Supplementary Figure
Table 1. Patient baseline characteristics among all patients randomised in the Phase II study (NCT00753545) (Ledermann et al,
2012, 2014)
Overall population BRCAm gBRCAm BRCAwt
Olaparib
(n¼136)
Placebo
(n¼129)
Olaparib
(n¼74)
Placebo
(n¼62)
Olaparib
(n¼53)
Placebo
(n¼43)
Olaparib
(n¼57)
Placebo
(n¼61)
Age, years, median (range) 58 (21–89) 59 (33–84) 58 (38–89) 55 (33–84) 56 (38–89) 55 (33–84) 62 (21–80) 63 (49–79)
Jewish ancestry,a n (%) 20 (15) 17 (13) 14 (19) 14 (23) 10 (19) 12 (28) 6 (11) 3 (5)
ECOG performance status, n (%)
0 110 (81) 95 (74) 62 (84) 45 (73) 47 (89) 32 (74) 45 (79) 45 (74)
1 23 (17) 30 (23) 11 (15) 15 (24) 5 (9) 10 (23) 10 (18) 14 (23)
2 1 (1) 2 (2) 0 1 (2) 0 (0) 1 (2) 1 (2) 1 (2)
Unknown 2 (2) 2 (2) 1 (1) 1 (2) 1 (2) 0 (0) 1 (2) 1 (2)
Primary tumour location, n (%)
Ovary 119 (88) 109 (85) 65 (88) 54 (87) 47 (89) 37 (86) 50 (88) 49 (80)
Fallopian tube or primary peritoneal 17 (13) 19 (15) 9 (12) 8 (13) 6 (11) 6 (14) 7 (12) 11 (18)
Other 0 1 (1) 0 0 0 0 0 1 (2)
Time to progression after completion of most
recent platinum-based regimen, n (%)
46 to p12 months 53 (39) 54 (42) 28 (38) 26 (42) 22 (42) 21 (49) 23 (40) 24 (39)
412 months 83 (61) 75 (58) 46 (62) 36 (58) 31 (58) 22 (51) 34 (60) 37 (61)
Objective response to most recent platinum-
based regimen, n (%)
Complete response 57 (42) 63 (49) 36 (49) 34 (55) 29 (55) 22 (51) 20 (35) 25 (41)
Partial response 79 (58) 66 (51) 38 (51) 28 (45) 24 (45) 21 (49) 37 (65) 36 (59)
Abbreviations: BRCAm¼BRCA mutation; BRCAwt¼BRCA wild type; ECOG¼Eastern Cooperative Oncology Group; gBRCAm¼germline BRCAm. aAncestry was self-reported.
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S2a and b). Details of further subscales are provided in
Supplementary Figure S3. The greatest decrease was observed at
month 1 for olaparib and month 4 for placebo (overall population,
BRCAm and gBRCAm). In the overall population, there was no
statistically significant difference in median time to TOI worsening
with olaparib vs placebo, although the median time to worsening
was numerically shorter with olaparib (3.8 vs 4.6 months,
respectively; hazard ratio (HR) 1.08; 95% CI 0.75, 1.55; P¼ 0.7).
Median time to TOI worsening was numerically longer with
olaparib vs placebo for BRCAm patients (5.7 vs 3.7 months,
respectively; HR 0.8; 95% CI 0.48, 1.34; P¼ 0.4) and gBRCAm
patients (7.4 vs 3.6 months, respectively; HR 0.54 95% CI 0.30,
0.99; P¼ 0.048). There was no HRQoL detriment in the overall,
BRCAm and gBRCAm populations.
FOSI. In the overall population, the percentage of patients with a
best response of ‘improved’ in FOSI was similar between treatment
groups (17% vs 15% for olaparib vs placebo; Table 2), with no
significant differences (OR 1.22; 95% CI 0.60, 2.51; P¼ 0.59).
These values were 21% vs 16%, respectively, in BRCAm patients
(OR 1.41; 95% CI 0.56, 3.70; P¼ 0.47) and 26% vs 13%,
respectively, in gBRCAm patients (OR 2.31; 95% CI 0.75, 8.10;
P¼ 0.15). Supplementary Table S2 provides further details for the
time-to-worsening analysis using Cox’s proportional hazards
model for FOSI.
Patient experience of important symptoms on FOSI remained
consistent with baseline and comparable between treatment groups
and over time (Figure 2a–c and Supplementary Figure S2c–d).
Baseline mean FOSI scores±s.d. were 26.1±3.4 with olaparib and
25.4±3.8 with placebo for the overall population; 25.9±3.4 and
24.8±4.1, respectively, for BRCAm patients; and 25.8±3.3 and
25.1±4.1, respectively, for gBRCAm patients. In the overall
population, median time to FOSI worsening was 2.8 vs 3.7 months
for olaparib and placebo, respectively; there was no significant
difference (HR 1.22; 95% CI 0.88, 1.71; P¼ 0.228). Median time to
FOSI worsening was 2.8 vs 3.7 months, respectively, in BRCAm
patients (HR 1.15; 95% CI 0.74, 1.81; P¼ 0.53) and 3.7 vs 3.3
months, respectively, in gBRCAm patients (HR 0.71; 95% CI 0.42,
1.22; P¼ 0.212).
FACT-O. No statistically significant differences were observed
between treatment groups (21% vs 19% for olaparib vs placebo) for
improvement in the FACT-O score in the overall population (OR
1.17; 95% CI 0.60, 2.27; P¼ 0.65). In BRCAm patients, the
percentage of patients with a best response of ‘improved’ was 27%
vs 21% for olaparib vs placebo, respectively (OR 1.38; 95% CI 0.58,
3.39; P¼ 0.47). These values were 29% vs 11%, respectively, for
gBRCAm patients (OR 3.26; 95% CI 1.00, 12.9; P¼ 0.05).
Supplementary Table S2 provides further details for the time-to-
worsening analysis using Cox’s proportional hazards model for
FACT-O.
The FACT-O total score remained consistent with baseline and
comparable between groups and over time (Figure 3a–c and
Supplementary Figure S2e–f). Baseline mean FACT-O scores±s.d.
were 121.9±17.3 with olaparib and 119.7±17.4 with placebo for
the overall population; 118.9±18.1 and 115.9±18.9, respectively,
for BRCAm patients; and 119.5±18.5 and 118.6±17.2, respec-
tively, for gBRCAm patients. Time to FACT-O score worsening in
the overall population was numerically shorter with olaparib vs
placebo (2.8 vs 4.6 months, respectively; HR 1.16; 95% CI 0.83,
1.64; P¼ 0.39). There were no clinically relevant or statistically
significant differences in FACT-O score time to worsening for
BRCAm patients (3.2 vs 4.4 months, respectively; HR 1.04; 95%
CI 0.65, 1.69; P¼ 0.87) or gBRCAm patients (3.2 vs 3.7 months,
respectively; HR 0.84; 95% CI 0.48, 1.48; P¼ 0.55).
Nausea, vomiting and fatigue. Minimal changes were observed
during the course of treatment for nausea, vomiting and fatigue
Table 2. HRQoL best response for the overall population and by BRCA status
Overall population, n (%) BRCAm, n (%) gBRCAm, n (%)
Olaparib Placebo Olaparib Placebo Olaparib Placebo
TOI n¼115 n¼111 n¼64 n¼53 n¼ 45 n¼37
Baseline score, mean (s.d.) 81.7 (11.8) 81.5 (11.6) 79.9 (12.1) 79.5 (12.1) 79.5 (12.3) 81.0 (11.0)
Improved 23 (20.0) 20 (18.0) 16 (25.0) 10 (18.9) 12 (26.7) 3 (8.1)
No change 72 (62.6) 67 (60.4) 38 (59.4) 30 (56.6) 27 (60.0) 22 (59.5)
Worsened 16 (13.9) 20 (18.0) 7 (10.9) 10 (18.9) 4 (8.9) 9 (24.3)
Non-evaluable 4 (3.5) 4 (3.6) 3 (4.7) 3 (5.7) 2 (4.4) 3 (8.1)
FOSI n¼117 n¼115 n¼66 n¼56 n¼ 46 n¼39
Baseline score, mean (s.d.) 26.1 (3.4) 25.4 (3.8) 25.9 (3.4) 24.8 (4.1) 25.8 (3.3) 25.1 (4.1)
Improved 20 (17.1) 17 (14.8) 14 (21.2) 9 (16.1) 12 (26.1) 5 (12.8)
No change 74 (63.2) 74 (64.3) 39 (59.1) 36 (64.3) 26 (56.5) 23 (59.0)
Worsened 20 (17.1) 21 (18.3) 11 (16.7) 9 (16.1) 6 (13.0) 9 (23.1)
Non-evaluable 3 (2.6) 3 (2.6) 2 (3.0) 2 (3.6) 2 (4.3) 2 (5.1)
FACT-O n¼114 n¼111 n¼63 n¼53 n¼ 45 n¼37
Baseline score, mean (s.d.) 121.9 (17.3) 119.7 (17.4) 118.9 (18.1) 115.9 (18.9) 119.5 (18.5) 118.6 (17.2)
Improved 24 (21.1) 21 (18.9) 17 (27.0) 11 (20.8) 13 (28.9) 4 (10.8)
No change 68 (59.6) 63 (56.8) 35 (55.6) 26 (49.1) 25 (55.6) 19 (51.4)
Worsened 20 (17.5) 24 (21.6) 10 (15.9) 14 (26.4) 6 (13.3) 12 (32.4)
Non-evaluable 2 (1.8) 3 (2.7) 1 (1.6) 2 (3.8) 1 (2.2) 2 (5.4)
Nausea n¼115 n¼113 n¼64 n¼54 n¼ 44 n¼37
Improved 5 (4.3) 11 (9.7) 0 (0) 6 (11.1) 0 (0) 4 (10.8)
No change 69 (60.0) 77 (68.1) 43 (67.2) 38 (70.4) 31 (70.5) 24 (64.9)
Worsened 37 (32.2) 19 (16.8) 18 (28.1) 5 (9.3) 12 (27.3) 4 (10.8)
Non-evaluable 4 (3.5) 6 (5.3) 3 (4.7) 5 (9.3) 1 (2.3) 5 (13.5)
Vomiting n¼115 n¼111 n¼65 n¼54 n¼ 46 n¼38
Improved 6 (5.2) 5 (4.5) 2 (3.1) 2 (3.7) 2 (4.3) 1 (2.6)
No change 95 (82.6) 94 (84.7) 54 (83.1) 45 (83.3) 38 (82.6) 31 (81.6)
Worsened 7 (6.1) 6 (5.4) 3 (4.6) 3 (5.6) 3 (6.5) 2 (5.3)
Non-evaluable 7 (6.1) 6 (5.4) 6 (9.2) 4 (7.4) 3 (6.5) 4 (10.5)
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in the overall population (Supplementary Figure S4). Most
patients did not report nausea at baseline or discontinuation. At
baseline, the mean nausea score was 3.77 with olaparib and 3.71
with placebo in the overall population, with a shorter median
time to nausea worsening with olaparib (1.1 months) than
placebo (6.5 months). Although olaparib patients experienced
more nausea during the first months of treatment and a higher
proportion had a best response of ‘worsening’ vs placebo (32.2%
vs 16.8%, respectively), scores became similar with increasing
time on olaparib. In gBRCAm patients, decreases in nausea
scores were transient and only observed at month 1.
The percentage of patients with a score of 3 or 4 (symptoms:
‘a little bit’ or ‘not at all’) for nausea was consistently above
65% (olaparib) and 75% (placebo) in the overall population;
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Figure 1. TOI change from baseline to 6 months for (A) the overall
population and patients with (B) BRCAm and (C) gBRCAm. Worsening
of TOI indicated with a negative score. Olaparib/Placebo indicates the
number of patients who completed the assessment at each time point.
Abbreviations: CI¼ confidence interval; LSM¼ least squares mean.
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Figure 2. FOSI change from baseline to 6 months for (A) the overall
population and patients with (B) BRCAm and (C) gBRCAm. Worsening
of FOSI indicated with a negative score. Olaparib/Placebo indicates the
number of patients who completed the assessment at each time point.
Abbreviations: CI¼ confidence interval; LSM¼ least squares mean.
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these values were 60 and 65%, respectively, for BRCAm patients
and 60% and 75%, respectively, for gBRCAm patients. There
were no differences in vomiting or fatigue scores between the
olaparib and placebo groups in the overall, BRCAm or gBRCAm
populations (Supplementary Figure S4b and c).
DISCUSSION
Stability of HRQoL with acceptable side effects of treatment is an
important consideration for patients with recurrent ovarian cancer
receiving maintenance therapy after response to chemotherapy. In
this study, there were no statistically significant or clinically
relevant differences in HRQoL between treatment arms on TOI,
total FACT-O and FOSI assessments among all patients and in the
BRCAm or gBRCAm subgroups. These data demonstrate that
maintenance treatment with olaparib had no apparent adverse
impact on HRQoL in patients with PSR SOC, which is also
supported by the high compliance with treatment and very low
discontinuation rates because of AEs.
Evidence of maintained HRQoL complements and provides
additional support of the primary study results of a significantly
prolonged PFS with olaparib vs placebo (difference in median PFS
3.6 months, Po0.001), with BRCAm patients most likely to benefit
(difference in median PFS 6.9 months, Po0.0001). In addition,
AEs in this study were generally manageable (Ledermann et al,
2012, 2014). Olaparib did not appear to affect patients’ experience
of vomiting, with similar scores between olaparib- and placebo-
treated patients across all time points. Olaparib patients experi-
enced more early nausea and, to a lesser extent, fatigue, but this is
consistent with known AE profiles and, with increasing time on
therapy, scores became similar to those for placebo. This is
reflected by the initial worsening of physical wellbeing scores in
olaparib-treated patients, however, after 4 months of treatment
with olaparib the HRQoL scores were similar to those in patients
treated with placebo.
The patient population evaluated in the current study included
patients with complete or partial responses to chemotherapy. As
expected, baseline HRQoL scores in this group were relatively high
compared with scores from other cancer cohorts. These high
baseline scores are a consideration when interpreting time-to-
worsening measures, particularly those for vomiting, which was
not a prominent symptom impacting patients in either arm of the
study at entry. A trend towards a higher proportion of patients in
the overall population reporting improvements in TOI, FOSI and
total FACT-O following treatment with olaparib vs placebo was
seen across the endpoints evaluated. It is possible that any
improvement during the maintenance treatment phase reflects
recovery from the side effects of prior treatment, rather than from
amelioration of cancer-related symptoms, as these would be
expected to be minimal at study entry for patients whose disease is
in response.
The HRQoL finding in gBRCAm patients is worth emphasising.
Although the least number of patients was included in this
subgroup analysis, patient numbers were not much smaller than
those in the BRCAm subset. As the study design did not include a
spending strategy to control type I error rates among the patient-
reported outcome (PRO) endpoints, all analyses should be
considered exploratory and the P-values nominal. Of the 136
BRCAm patients in this Phase II study, 96 were known to have a
gBRCAm (Ledermann et al, 2014). It is unknown whether these
findings originate from a biological basis.
Limitations of this study include HRQoL data not being
collected beyond disease progression. Patients with progressive
disease usually receive further courses of chemotherapy, an
intervention associated with reductions in HRQoL. Olaparib
significantly delays progression (Ledermann et al, 2012); therefore,
post-progression patient outcome data may have indicated a
benefit with olaparib. Delays in time to first subsequent therapy or
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Figure 3. FACT-O total score change from baseline to 6 months
for (A) the overall population and patients with (B) BRCAm and
(C) gBRCAm. Worsening of FACT-O indicated with a negative score.
Olaparib/Placebo indicates the number of patients who completed the
assessment at each time point. Abbreviations: CI¼ confidence interval;
LSM¼ least squares mean.
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death (TFST) may also delay detriments in HRQoL; it is of interest
that future studies collect HRQoL data during PFS, TFST and
beyond. Additionally, this analysis is limited in that primary and
secondary PRO hypotheses were not defined prior to the study.
At the time of the development of this study, there were limited
studies on the QoL of cancer patients receiving maintenance
treatment and there were no specifically agreed PRO or QoL
assessments for use in this setting in oncology trials. Studies in
other cancer types, such as non-small-cell lung cancer and
metastatic breast cancer, where maintenance treatment is more
common, have used a range of QoL assessments, including cancer-
specific variations of the EORTC QLQ-C30, EuroQol 5-dimen-
sional questionnaire (EQ-5D) and FACT tools (Gridelli et al, 2012;
Park et al, 2015; Spigel et al, 2015). More recently, the importance
of QoL assessments during clinical trials has been noted
(Friedlander and King, 2013) and specific guidance such as the
CONSORT-PRO recommendations should be followed in future
trials (Calvert et al, 2013). The Phase III study of olaparib
maintenance treatment in patients with BRCAm PSR ovarian
cancer (SOLO2; NCT01874353) has included several predefined
QoL endpoints to better assess the impact of this treatment on
QoL. Finally, although the compliance rate of approximately 80%
is favourable, it is incomplete. Reasons for reduced HRQoL
assessment completion included no validated Ukrainian translation
of the FACT-O questionnaire and administrative failure in
questionnaire distribution.
In conclusion, olaparib maintenance therapy demonstrated no
detrimental impact on HRQoL outcomes compared with placebo.
Phase III trials of olaparib in patients with BRCA-mutated ovarian
cancer are ongoing (NCT01844986, NCT01874353 and
NCT02282020). These studies will assess HRQoL using the
FACT-O and EQ-5D-5L (five-level EuroQol) assessments and will
collect HRQoL data over a longer period, beyond disease
progression.
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